NasdaqGS:ARWRBiotechs
Arrowhead Pharmaceuticals (ARWR) Valuation Check After Australian Approval Expands REDEMPLO Opportunity
Arrowhead Pharmaceuticals (ARWR) is back in focus after Australia’s Therapeutic Goods Administration approved REDEMPLO (plozasiran) to treat adults with familial chylomicronemia syndrome, extending the drug’s reach beyond the United States, Canada, and China.
See our latest analysis for Arrowhead Pharmaceuticals.
Those regulatory wins appear to be reflected in the share price, with a 25.17% 1 month share price return and a 12.69% year to date share price return, alongside a 1 year total...